{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(1)"],"submitter":["Zhao QH"],"pubmed_abstract":["This study aimed to evaluate the effectiveness and safety of an oral sequential triple combination therapy with selexipag after dual combination therapy with endothelin receptor antagonist (ERA) and phosphodiesterase-5 inhibitor (PDE5I)/riociguat in pulmonary arterial hypertension (PAH) patients. A total of 192 PAH patients from 10 centers had received oral sequential selexipag therapy after being on dual-combination therapy with ERA and PDE5i/riociguat for a minimum of 3 months. Clinical data were collected at baseline and after 6 months of treatment. The study analyzed the event-free survival at 6 months and all-cause death over 2 years. At baseline, the distribution of patients among the risk groups was as follows: 22 in the low-risk group, 35 in the intermediate-low-risk group, 91 in t"],"journal":["Pulmonary circulation"],"pagination":["e12351"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10925724"],"repository":["biostudies-literature"],"pubmed_title":["Evaluating the efficacy and safety of oral triple sequential combination therapy for treating patients with pulmonary arterial hypertension: A multicenter retrospective study."],"pmcid":["PMC10925724"],"pubmed_authors":["Guo JZ","Chen J","Zhou YL","Feng KF","Zhao QH","Chen FD","Ruan HY","Wang L","Zhang W","Gong SG","Xu XL","Wang QQ","Zhang RF"],"additional_accession":[]},"is_claimable":false,"name":"Evaluating the efficacy and safety of oral triple sequential combination therapy for treating patients with pulmonary arterial hypertension: A multicenter retrospective study.","description":"This study aimed to evaluate the effectiveness and safety of an oral sequential triple combination therapy with selexipag after dual combination therapy with endothelin receptor antagonist (ERA) and phosphodiesterase-5 inhibitor (PDE5I)/riociguat in pulmonary arterial hypertension (PAH) patients. A total of 192 PAH patients from 10 centers had received oral sequential selexipag therapy after being on dual-combination therapy with ERA and PDE5i/riociguat for a minimum of 3 months. Clinical data were collected at baseline and after 6 months of treatment. The study analyzed the event-free survival at 6 months and all-cause death over 2 years. At baseline, the distribution of patients among the risk groups was as follows: 22 in the low-risk group, 35 in the intermediate-low-risk group, 91 in t","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jan","modification":"2026-07-15T20:13:21.711Z","creation":"2024-12-04T09:28:20.038Z"},"accession":"S-EPMC10925724","cross_references":{"pubmed":["38468630"],"doi":["10.1002/pul2.12351"]}}